Guest Editors
Mari Mino-Kenudson (Fig.1)
Department of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA
Lung cancer is the leading cause of cancer death worldwide and represents 19% of all cancer-related deaths. In the US, the majority, about 60% of patients, present with stage IV disease, and the 5-year overall survival (OS) rate is 4.5% for stage IV and 18% for all stages. Even those who presented with stage I tumors, 45% will die at 5 years. Thus, there have been multiple efforts to improve the survival of not only patients with advanced disease, but also those with early stage tumors. In this focused issue of Translational Lung Cancer Research, the above important topics are discussed in depth. Hopefully, the readers will enjoy the collection of timely articles and apply valuable pieces of information to their daily practice.
